Increasing prevalence of sleep bruxism are expected to boost the growth of the global sleeping bruxism treatment market at a CAGR of 5.95% during the forecast period of 2022 to 2030

Market Research Future (MRFR) has published a cooked research report on the “Global Sleeping Bruxism Treatment Market” that contains the information from 2022 to 2030.

Market Highlights

The global sleeping bruxism treatment market is expected to register a CAGR of 5.95% during the forecast period and is expected to hit USD 934.90 million by 2030.

Sleeping bruxism is defined as that rhythmic clenching and grinding activity of jaw muscles which is characterized by oral parafunction at subconscious level. The prevalence of this disease is equally found in male and female. Awareness related to early detection of sleep bruxism would be helpful in reducing risk of damage face structure.

The growth of the global sleeping bruxism treatment market is expected to be driven by increasing prevalence of sleep bruxism and growing child population. However, limited availability of treatment options hampers the growth of this market.

Key Players

MRFR recognizes the following companies as the key players in the global Sleeping Bruxism Treatment market— Ivoclar Vivadent AG (Liechtenstein), Ipsen S.A. (France), Merz Pharma GmbH & Co. KGaA (Germany), Carestream Dental (US), Akervall Technologies Inc (US), Planmeca Oy (Finland), Randmark Dental Products, LLC (US), S4S (UK) Limited (UK), Patterson Dental Supply, Inc (US), Henry Schein, Inc (US), Pfizer, Inc (US).

Segment Analysis

The global sleeping bruxism treatment market is mainly segmented into type, cause, treatment, and test type, end user. On the basis of type, the sleeping bruxism treatment market has been bifurcated into primary bruxism, secondary bruxism. Treatment category is segmented into dental approaches, medication. The dental approaches segment is further sub-segmented into mouth guard, NTI-tss device. The medication segment is categorized into muscle relaxants, botox injections, anti-anxiety drugs. On the basis of cause, the sleeping bruxism treatment market has been bifurcated into obstructive sleep apnea (OSA), gastroesophageal reflux disease (GERD), malocclusion, sleep paralysis. On the basis of patient type pediatric, adult. The adult segment is categorized into male, female. By end user, the sleeping bruxism treatment market is bifurcated into hospitals & clinics, dental clinics.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Sleeping Bruxism Treatment Market Research Report

Regional Analysis

The global sleeping bruxism treatment market has been segmented on the basis of region into Americas, Europe, Asia-Pacific, and Middle East & Africa. The Americas held the largest market share of 39.3% based on region and is anticipated to dominate the overall sleeping bruxism treatment market during the forecast period.

The major factors driving Americas sleeping bruxism treatment market are rising prevalence of stress and anxiety among the population, presence of key players in the region, and well-established dental industry. According to the Anxiety & Depression Association of America, anxiety disorders affect about 40 million adults in the US, or 18.1% of the population every year. Moreover, according to the National Institutes of Health, more than 40 million Americans suffer from chronic, long-term sleep disorders, and an additional 20 million report sleeping problems occasionally. Furthermore, the American Sleep Association estimates that sleeping bruxism affects 10% of the adult population and 15% of the children population.

Europe holds the second largest market share due to the high incidence of sleeping disorders. According to the European Orthodontic Society (2014–2015), sleeping bruxism affects 14 to 20% of children, 8 to 12% of teenagers, and 3% of the elderly population. In addition, the Journal of Oral Rehabilitation shows that 5.0% of the total adult Dutch population had awake bruxism, and 16.5% had sleep bruxism. According to The Bruxism Association, people suffering from other sleeping disorders such as snoring, obstructive sleep apnea, sleep talking, violent behavior during sleep, and sleep paralysis are often more at risk for bruxism. Moreover, people with a stressful lifestyle, smokers, people with a high alcohol intake, people who drink six or more cups a day of tea or coffee, and people who take medication for sleep, depression and/or anxiety are also at significant risk for bruxism.

Asia-Pacific is the fastest-growing regional market for sleeping bruxism treatment due to the rapid adoption of advanced healthcare technology, fast economic growth, large population size, and rising healthcare investments. The rising child population also provides favorable background for the market to grow. According to UNICEF, in 2016, South Asia has 627 million children, i.e., 36% of the total population. Moreover, raising awareness of sleep bruxism and rapidly growing the dental industry in countries such as China, India, Japan, and South Korea is likely to fuel the market growth. Furthermore, there has been a growing prevalence of mental illness, including stress, anxiety, and depression, and sleep-related disorders such as sleep apnea in the region. 

The sleeping bruxism treatment market in the Middle East & Africa is expected to witness steady growth due to the growth in the medical industry owing to increasing R&D expenditures and investments in clinical trials and manufacturing. Moreover, improving healthcare infrastructure in the region, especially in Africa, is anticipated to drive market growth.

Key Findings of the Study

• 
  

  The Sleeping Bruxism Treatment Market is projected to reach USD 934.90 Million by 2030 at 5.95% CAGR during the forecast period 2022-2030.

  
  


• Based on type, the primary bruxism segment accounted for the largest market share of 26.9% in 2020.


• By treatment, the dental approaches segment dominated the market with a share of 69.2% in 2020.


• On the basis of cause, the obstructive sleep apnea segment dominated the market with a share of 36.2% in 2020.


• Based on patient type, the pediatric segment dominated the market with a share of 69.0% in 2020.


• Based on end user, the hospitals & clinics segment dominated the market with a share of 43.00% in 2020.


• The Americas region accounted for the largest share of the global market, which is majorly attributed to the rising prevalence of stress and anxiety among the population, presence of key players in the region, and well-established dental industry.